In recent years, Europe has learned a tough lesson: when it comes to critical technologies, strategic autonomy matters. From microchips to energy, the continent has taken bold steps to secure its industrial and scientific independence.
Biomanufacturing is next—and cell manufacturing is at the heart of it.
Whether for advanced therapies, precision diagnostics, or cultivated food, sensitive cell production is becoming a strategic capability. Yet today, Europe still relies heavily on imported equipment, high-cost infrastructures, and complex supply chains.
At Cellura, we believe the future of health and sustainable food must be made in Europe—with scalable, accessible bioreactors designed to serve both research and industry.
Why Sovereignty in Cell Manufacturing Matters
The European health and food sectors are rapidly evolving:
- Cell therapies and organoids are entering clinical pipelines
- Meat cultivated from animal cells is gaining regulatory traction
- In vitro alternatives to animal testing are now actively encouraged by regulators (FDA Modernization Act 2.0, EU policy roadmap)
All these revolutions rely on one key resource: the ability to manufacture fragile cells at scale.
But this capability is still concentrated in a few labs or foreign players. The risk? Dependency, cost explosion, limited access for academic centers, and vulnerability to external supply shocks.
Cellura’s Vision: European-Designed, Scale-Ready Bioproduction
Founded in Marseille, Cellura is pioneering a new generation of bioreactors tailored to sensitive cells and European needs.
Our SoftXS platform is:
- Manufactured in France
- Built for modular scalability, from 135 mL to industrial volumes
- Designed for low-shear cytocentric culture, reducing cellular stress
- Available as single-use versions, fully compatible with GMP and academic environments
This approach allows labs, biotech startups, and CDMOs to produce their own critical cell types—in-house, at lower cost, and without waiting for external capacity.
Democratizing Access, Empowering Local Innovation
We believe that sovereignty starts by empowering scientists where they are.
SoftXS bioreactors are already being evaluated in academic labs and biotech accelerators. By removing the usual entry barriers (cost, complexity, inflexibility), Cellura supports:
- Academic breakthroughs in iPSC, immune cells, and organoid research
- Emerging biotechs focused on cell therapies, diagnostics, or agri-tech
- Localized production hubs that reduce dependency on central facilities
Whether for decentralized medicine or resilient food systems, smart local manufacturing is key—and that starts with the right tools.
Call for European-Led Biomanufacturing
Europe already leads in regenerative medicine research, cell therapy patents, and life science innovation. What’s missing is the infrastructure to turn ideas into impact—at scale, at home.
That’s why we at Cellura are not just building bioreactors—we’re building a platform for scientific and industrial sovereignty.
Let’s make Europe the home of ethical, accessible, and sovereign cell manufacturing.
Because the future of biology should be made in Europe.
